Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 20/20 | 1.00 |
| ▸ | FNTB | P49356 | 20/20 | 1.00 |
| ▸ | HRAS | P01112 | 1/20 | 1.00 |
| ▸ | KRAS | P01116 | 1/20 | 1.00 |
| ▸ | PGGT1B | P53609 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bms-214662 SCHEMBL16499911 | 1.00 | FNTA (1.00) | FNTAFNTBHRASKRASPGGT1B | |
| Bms-214662 SCHEMBL30498791 | 0.99 | FNTA (0.99) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL22050803 | 0.93 | FNTA (0.86) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL13300962 | 0.89 | FNTA (0.80) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL10039032 | 0.89 | FNTA (0.80) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL17547679 | 0.89 | FNTA (0.80) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL29171478 | 0.88 | FNTA (0.79) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL7665888 | 0.87 | FNTA (0.77) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL15977117 | 0.87 | FNTA (0.77) | FNTAFNTBHRASKRASPGGT1B | |
| Bms-214662 SCHEMBL134854 | 0.85 | FNTA (0.74) | FNTAFNTBHRASKRASPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200129489-A1 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | DECIPHERA PHARMACEUTICALS, LLC | 2020-04-30 | — | — | US | claimed |
| US-9422281-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2016-08-23 | — | — | US | claimed |
| US-9388161-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | claimed |
| US-12043602-B2 | Fendiline derivatives | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-23 | — | — | US | disclosed |
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | VALO HEALTH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| CN-115243681-A | Compositions of 1- (4-bromo-5- (1-ethyl-7- (methylamino) -2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl) -2-fluorophenyl) -3-phenylurea | 德西费拉制药有限责任公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115135308-A | Amorphous kinase inhibitor formulations and methods of use thereof | 德西费拉制药有限责任公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20220177440-A1 | Fendiline Derivatives | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-06-09 | — | — | US | disclosed |
| CN-114569547-A | Preparation of brinciclovir | 奇默里克斯公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20220073452-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO HEALTH, INC. | 2022-03-10 | — | — | US | disclosed |
| EP-3932914-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Valo Health, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007109527-A1 | METHODS OF IDENTIFYING AND TREATING INDIVIDUALS EXHIBITING MUTANT BCR/ABL KINASE POLYPEPTIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| WO-2007059143-A2 | METHODS OF IDENTIFYING AND TREATING INDIVIDUALS EXHIBITING MDR-1 OVEREXPRESSION WITH PROTEIN TYROSINE KINASE INHIBITORS AND COMBINATIONS THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007011765-A2 | METHODS OF IDENTIFYING AND TREATING INDIVIDUALS EXHIBITING MUTANT SRC KINASE POLYPEPTIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073452-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | FNTA 3030/4885FNTB 2058/4885HRAS 1313/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | FNTA 3062/4885FNTB 1584/4885HRAS 78/4885 |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, FDPS | FNTA 2/4885FNTB 1/4885HRAS 87/4885 |
| US-12043602-B2 | Fendiline derivatives | CYP11B2, CYP3A7, CYP4F2 | FNTA 1542/4885FNTB 862/4885HRAS 4671/4885 |
| US-20220177440-A1 | Fendiline Derivatives | CYP11B2, CYP3A7, CYP4F2 | FNTA 1542/4885FNTB 862/4885HRAS 4671/4885 |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | FNTA 3062/4885FNTB 1584/4885HRAS 78/4885 |
| US-20200129489-A1 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | PDGFRA, PDGFRB, ALK | FNTA 3530/4885FNTB 2759/4885HRAS 32/4885 |
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | FNTA 3030/4885FNTB 2058/4885HRAS 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.